Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
Pf-00610355
Class :
Antiasthmatic drugs/adrenergic agonists/beta-agonists
Brand Name :
N/A
Synonyms :
Pf-00610355
Class :
Antiasthmatic drugs/adrenergic agonists/beta-agonists
Dosage Forms & Strengths
Solution for inhalation
450mcg
Chronic Obstructive Pulmonary Disease (COPD)
280
mcg
Inhalation
once a day
Off-label
Dosage Forms & Strengths
Safety and efficacy studies are not established
Refer to adult dosing
the therapeutic effect of pf-00610355 may be reduced
the risk of hypertension may be increased
the risk of hypertension may be increased
the risk of hypertension may be increased
the risk of tachycardia may be increased
the risk of hypertension may be increased
the therapeutic effect of pf-00610355 may be increased
the antihypertensive activity of aliskiren may be reduced
the risk of hypertension may be increased
the risk of hypertension may be increased
the therapeutic effect of pf- 00610355 may be reduced
the risk of hypertension may be increased
the risk of adverse effects may be increased
the risk of hypokalemia may be increased
the antihypertensive activity of benazepril may be reduced
the risk of hypertension may be increased
the risk of tachycardia may be increased
the antihypertensive activity of bepridil may be reduced
the therapeutic effect of pf-00610355 may be reduced
the risk of tachycardia may be increased
the antihypertensive activity of bosentan may be reduced
the risk of hypertension may be increased
Actions and spectrum:
By using a sulfonamide agonist headgroup, pf-00610355 exhibits high levels of intrinsic crystallinity, which may be related to the acidic sulfonamide motif that supports a zwitterionic form in the solid state. Reducing adverse events mediated by the system and minimizing systemic exposure after inhalation was achieved through the optimization of pharmacokinetic properties.
Black Box Warning
No special black box warnings are available for this product
Contraindication/Caution:
Contraindication:
Hypersensitivity
Pregnancy consideration:
Safety and efficacy study is not established
Lactation:
Safety and efficacy study is not established
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pf-00610355 is a beta-2 adrenergic agonist.
Pharmacodynamics:
It is an ultra-long-acting beta-adrenergic receptor agonist.
Pharmacokinetics:
Limited data available
Administration:
The drug is being studied.
Patient information leaflet
Generic Name: pf-00610355
Why do we use pf-00610355?
The inhalable (ultra-long-acting β2 adrenoreceptor agonist) ultra-LABA, PF-610355 (also known as PF-00610355 or PF-610,355), was studied for the treatment of COPD and asthma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
